DK3157549T3 - Hidtil ukendt immunterapi mod flere forskellige tumorer i blodet, navnlig kronisk lymfatisk leukæmi (CLL) - Google Patents

Hidtil ukendt immunterapi mod flere forskellige tumorer i blodet, navnlig kronisk lymfatisk leukæmi (CLL) Download PDF

Info

Publication number
DK3157549T3
DK3157549T3 DK15730135.9T DK15730135T DK3157549T3 DK 3157549 T3 DK3157549 T3 DK 3157549T3 DK 15730135 T DK15730135 T DK 15730135T DK 3157549 T3 DK3157549 T3 DK 3157549T3
Authority
DK
Denmark
Prior art keywords
cll
immunotherapy
several different
lymphocytic leukemia
chronic lymphocytic
Prior art date
Application number
DK15730135.9T
Other languages
Danish (da)
English (en)
Inventor
Juliane Stickel
Daniel Kowalewski
Hans-Georg Rammensee
Stefan Stevanovic
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Application granted granted Critical
Publication of DK3157549T3 publication Critical patent/DK3157549T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK15730135.9T 2014-06-20 2015-06-17 Hidtil ukendt immunterapi mod flere forskellige tumorer i blodet, navnlig kronisk lymfatisk leukæmi (CLL) DK3157549T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462014849P 2014-06-20 2014-06-20
GBGB1411037.3A GB201411037D0 (en) 2014-06-20 2014-06-20 Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
PCT/EP2015/063566 WO2015193359A2 (en) 2014-06-20 2015-06-17 Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)

Publications (1)

Publication Number Publication Date
DK3157549T3 true DK3157549T3 (da) 2020-06-22

Family

ID=51409910

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15730135.9T DK3157549T3 (da) 2014-06-20 2015-06-17 Hidtil ukendt immunterapi mod flere forskellige tumorer i blodet, navnlig kronisk lymfatisk leukæmi (CLL)

Country Status (14)

Country Link
EP (2) EP3157549B1 (enExample)
JP (1) JP6560261B2 (enExample)
CA (1) CA2950827A1 (enExample)
DK (1) DK3157549T3 (enExample)
ES (1) ES2802155T3 (enExample)
GB (1) GB201411037D0 (enExample)
HU (1) HUE050070T2 (enExample)
LT (1) LT3157549T (enExample)
PL (1) PL3157549T3 (enExample)
PT (1) PT3157549T (enExample)
RS (1) RS60592B1 (enExample)
SI (1) SI3157549T1 (enExample)
TW (3) TW201930347A (enExample)
WO (1) WO2015193359A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201408255D0 (en) * 2014-05-09 2014-06-25 Immatics Biotechnologies Gmbh Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
KR20180100302A (ko) 2015-10-23 2018-09-10 우니베르지태트 트벤테 인테그린 결합 펩티드 및 그의 용도
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
MA55153A (fr) 2016-02-19 2021-09-29 Immatics Biotechnologies Gmbh Nouveaux peptides et combinaison de peptides pour une utilisation dans l'immunothérapie contre le lymphome non hodgkinien et d'autres cancers
GB201602918D0 (en) 2016-02-19 2016-04-06 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
CN116375797A (zh) 2016-03-01 2023-07-04 伊玛提克斯生物技术有限公司 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
GB201603987D0 (en) * 2016-03-08 2016-04-20 Immatics Biotechnologies Gmbh Uterine cancer treatments
BR112018070873A2 (pt) 2016-04-21 2019-02-05 Immatics Biotechnologies Gmbh imunoterapia contra melanoma e outros cânceres
CR20200608A (es) 2016-04-21 2021-01-20 Immatics Biotechnologies Gmbh INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551)
DE102016005550B4 (de) 2016-05-09 2024-09-26 Hans-Georg Rammensee Adjuvans zur lnduzierung einer zellulären lmmunantwort
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
CN107602682A (zh) * 2016-07-07 2018-01-19 胡国田 一种多肽及其应用
TWI796299B (zh) 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018189152A2 (en) * 2017-04-10 2018-10-18 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
BR112019021094A2 (pt) 2017-04-10 2020-05-12 Immatics Biotechnologies Gmbh Peptídeos e combinações dos mesmos para uso na imunoterapia contra leucemias e outros cânceres
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
DE102018107224A1 (de) 2018-02-21 2019-08-22 Immatics Biotechnologies Gmbh Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
US10925947B2 (en) 2018-06-29 2021-02-23 Immatics Biotechnologies Gmbh A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh) 2018-07-31 2020-06-01 德商英麥提克生物技術股份有限公司 B*07 限制肽和肽組合的抗癌免疫治療和相關方法
WO2020035123A1 (en) * 2018-08-11 2020-02-20 Baerlecken Niklas Autoantibodies binding to negative elongation factor e (nelf-e) for diagnosing sarcoidosis
CN109593125A (zh) * 2018-12-12 2019-04-09 深圳市龙华区人民医院 基于前列腺癌干细胞标志物cd44的抗原表位多肽cd44-p1及其应用
IL296881A (en) * 2020-04-14 2022-12-01 Universit? De Montr?Al New antigens specific for acute myeloid leukemia (aml) and their uses

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da) 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
AU2002218269A1 (en) * 2000-11-15 2002-05-27 Apoxis Sa Proteins and dna sequences underlying these proteins used for treating inflammations
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
ATE427499T1 (de) * 2004-05-21 2009-04-15 Inst Systems Biology Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
EP1806358B1 (en) 2005-09-05 2010-03-17 Immatics Biotechnologies GmbH Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US20070248628A1 (en) * 2005-12-06 2007-10-25 Keller Lorraine H Immunogens in cancer stem cells
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
WO2012056407A1 (en) 2010-10-26 2012-05-03 Technion Research & Development Foundation Ltd. Antibodies which bind soluble t-cell receptor ligands
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors

Also Published As

Publication number Publication date
WO2015193359A3 (en) 2016-02-25
PL3157549T3 (pl) 2020-12-14
TW201930347A (zh) 2019-08-01
TW201613956A (en) 2016-04-16
TWI670282B (zh) 2019-09-01
PT3157549T (pt) 2020-07-01
EP3157549A2 (en) 2017-04-26
JP2017525336A (ja) 2017-09-07
EP3708185A3 (en) 2020-11-04
ES2802155T3 (es) 2021-01-15
CA2950827A1 (en) 2015-12-23
WO2015193359A2 (en) 2015-12-23
EP3708185A2 (en) 2020-09-16
SI3157549T1 (sl) 2020-08-31
TW202024125A (zh) 2020-07-01
JP6560261B2 (ja) 2019-08-14
EP3157549B1 (en) 2020-04-29
HUE050070T2 (hu) 2020-11-30
GB201411037D0 (en) 2014-08-06
LT3157549T (lt) 2020-08-10
RS60592B1 (sr) 2020-08-31

Similar Documents

Publication Publication Date Title
PL3157549T3 (pl) Nowa immunoterapia przeciwko szeregu nowotworom krwi, w szczególności przeciwko przewlekłej białaczce limfatycznej (CLL)
DK3183272T3 (da) Asymmetriske multispecifikke antistoffer
SI3145929T1 (sl) 5-kloro-2-difluorometoksifenil pirazolopirimidinove spojine, ki so zaviralci janusove kinaze
IL261904A (en) 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as apj agonists
DK3461821T3 (da) Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
DK3456339T3 (da) Hidtil ukendt immunterapi mod flere forskellige tumorer, såsom lungecancer, herunder NSCLC
DK3126395T3 (da) Multispecifikke antistoffer
HUE043457T2 (hu) Magasabb rendû ambiszonikus (HOA) háttércsatornák közötti korreláció csökkentése
LT4001311T (lt) Anti-pd-l1/pd-1 deriniai, skirti navikų gydymui
LT3110440T (lt) Anti-cd38 antikūnai, skirti ūminės limfoblastinės leukemijos gydymui
DK3188717T3 (da) Formulering, der omfatter partikler
LT3168219T (lt) Piridono dariniai, turintys tetrahidropiranilmetilo grupę
ITUB20153347A1 (it) Apparato per la videocomunicazione
HUE048088T2 (hu) Új, netrin-1 elleni ellenanyag
EP3157553A4 (en) Treatment for chronic lymphocytic leukemia (cll)
LT3294769T (lt) Daugybinei mielomai (dm) skirtas gydymas
LT3386997T (lt) Monomaleimidu funkcionalizuoti platinos junginiai, skirti vėžio terapijai
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
LT3347360T (lt) Junginiai, naudingi ror-gama-t slopinimui
DK3277284T3 (da) Hidtil ukendte terapier mod kræft
DK3194976T3 (da) Fremgangsmåder til udvælgelse af midler, som stabiliserer proteinkomplekser
EP3108962C0 (de) Probenträger
DK3368519T3 (da) Hidtil ukendte, heterocykliske antiøstrogener
IL261160B (en) Methods of treating acute myeloid leukemia